Promising Tests For Alzheimer's Patients
Drinking a milkshake-style medicine at breakfast seems to feed brain cells starved from Alzheimer's damage, researchers reported Monday. It is one of four promising experimental drugs poised for large-scale testing against the brain-destroying disease.
The milkshake drug, called Ketasyn, is a dramatically different way to approach dementia. It hinges on recent research suggesting diabetic-like changes in brain cells' ability to use sugar for energy play a role in at least some forms of Alzheimer's.
Special fatty acids in Ketasyn offer an alternate food source to rev up those hungry neurons, researchers told an international Alzheimer's meeting here Monday. In a study of 150 patients, adding Ketasyn to their regular medicines produced a small but important boost in mental functioning, but only in people who don't carry an Alzheimer's gene called ApoE4. Still, that is about half of all patients.
"We see this as a co-therapy," not a way to stop Alzheimer's, cautioned Dr. Lauren Constantini, a former Harvard scientist now with the company Accera Inc. that is developing the drug.
For the first time, reports CBS News medical correspondent Dr. Jon LaPook, scientists are targeting what they believe may be a root cause of Alzheimer's: brain damage from clumps of a protein called beta amyloid.
New drugs are testing three approaches: enzyme blockers to stop the amyloid from forming; a drug called Alzhemed to stop the amyloid from clumping; and vaccines to help the immune system clean up the amyloid, adds LaPook.
Monday brought frustrating news on that front: The first of those amyloid blockers to make it to large-scale, Phase III testing has hit a hurdle, and scientists will have to wait until at least month's end to learn if Alzhemed really works.
The problem is statistical, said lead researcher Dr. Paul Aisen of Georgetown University: Hospital-to-hospital differences in other medication use among the study's 1,000 participants prevent an immediate clear comparison of Alzhemed's role. Working with the Food and Drug Administration, researchers are adjusting for those variations, Aisen told the Alzheimer's Association's dementia prevention meeting.
Stay tuned, he said: There are some hints that Alzhemed-treated patients fared better.
Other drugs highlighted Monday:
"This is a robust effect," said Lilly researcher Dr. Eric Siemers. "How could you not do a Phase III study?"